about
Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition ModelImmunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique.Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.Weight changes during and after 6 months of breastfeeding in HIV-infected mothers receiving antiretroviral therapy in Malawi.Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings.Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique.Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique.Tumor necrosis factor-alpha, Interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected highly active antiretroviral therapy-treated and untreated pregnant women in Mozambique.Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique.Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay.Single-nucleotide polymorphisms in human β-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parametersImplementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settingsResistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission preventionTriple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral LoadIs total lymphocyte count a reliable predictor of the CD4 lymphocyte cell count in resource-limited settings?
P50
Q26778483-17C3F85A-0A8F-4B2E-9353-0749198D0276Q34240160-3E81942E-0409-4BA9-821B-03BC26D5BD34Q38452483-056E231E-9BC5-475E-BAEB-D968A6D28E2FQ43049052-7693AFF3-BC6C-475E-A31C-1ECFA44C4E1CQ43649738-7B004D0C-D258-40F6-81F5-A8B7EAD97D9AQ43811493-60CFD171-4D98-445B-9F57-C3557D499AD3Q44237932-3D01F9F5-159D-40D8-8FF5-361A52D0E7EEQ44495122-EEDD9092-28FE-48D9-B557-9EAFE6A1C241Q46813664-6F635E86-8718-4477-8074-FBC9E550550CQ54451501-B376F145-AD7F-4CFE-B2A6-B493B991D218Q57951598-8904ABF5-6679-4EC9-B7A8-DD9B0E339823Q57951606-F783F5EA-36E4-4B5B-873F-DF9A3958C25FQ57951608-5310657B-4670-4D03-9CD3-DDA3AA2E46B0Q57951616-94F34172-0DCA-48F9-A34E-6C8E9746A77EQ57951646-EE53FE25-2E47-49BD-BECA-DB168262D16D
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Giovanni Guidotti
@ast
Giovanni Guidotti
@en
Giovanni Guidotti
@es
Giovanni Guidotti
@nl
Giovanni Guidotti
@sl
type
label
Giovanni Guidotti
@ast
Giovanni Guidotti
@en
Giovanni Guidotti
@es
Giovanni Guidotti
@nl
Giovanni Guidotti
@sl
prefLabel
Giovanni Guidotti
@ast
Giovanni Guidotti
@en
Giovanni Guidotti
@es
Giovanni Guidotti
@nl
Giovanni Guidotti
@sl
P106
P1153
35334199100
P21
P214
31144928029554340684
P31
P396
IT\ICCU\CFIV\317904
P496
0000-0002-8462-2901
P569
1961-01-01T00:00:00Z
P735
P7859
viaf-31144928029554340684